FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 86 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR FDA Sends Out Warning To Dollar Tree For Selling “Potentially Unsafe... November 20, 2019 Contact X-ray Brachytherapy Dose Escalation Increases the Organ Preservation Rate in... November 29, 2024 EMA Recommends Extension of Therapeutic Indications for Enzalutamide March 28, 2024 Pursuing precision medicine in a flagship lung cancer trial July 15, 2020 Load more HOT NEWS Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... Cancer in My Community: Working Toward Early Diagnosis for Children With... Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal...
